About the Company
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALKS News
Alkermes PLC
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Alkermes plc Reports First Quarter 2024 Financial Results
2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. "The first quarter of 2024 marks our first full quarter as a profitable ...
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
DUBLIN, May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk.
Alkermes plc Q1 Earnings Summary
(RTTNews) - Below are the earnings highlights for Alkermes plc (ALKS): Earnings: $36.83 million in Q1 vs. -$41.85 million in the same period last year. EPS: $0.21 in Q1 vs. -$0.25 in the same ...
Alkermes plc (ALKS) Q1 2024 Earnings Call Transcript
Sandy, you may begin. Good morning. Welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter ended March 31, 2024. With me today are Richard ...
Alkermes: Q1 Earnings Snapshot
DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based ...
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...
Alkermes plc (ALKS)
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the ...
Alkermes plc Reports First Quarter 2024 Financial Results
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...